Fabhalta (Iptacopan HCl) Patent Expiration, LOE Window & CMS Spending

Fabhalta (Iptacopan HCl) by Novartis: FDA Orange Book core substance LOE 2041-05-25 (last listed 2041-07-15), 0 AB generics, $43.3M 2024 CMS Part D & Medicaid spend, and $45,205 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN218276 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-05-25
Last Listed Patent or Exclusivity Date2041-07-15
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$43.3M
2024 Medicare Part D Spend$32.5M
2024 Medicaid Spend$10.8M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($45,205 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.